AstraZeneca cancer drug breakthrough

Trials show potential of ‘combination therapies’

US investors target UK mental healthcare

Acadia’s purchase of Priory to unleash wave of consolidation

Wounded Theranos pins recovery on Arizona

Change in state’s laws was a lifeline for start-up

UN risks Zika clash with LatAm leaders

Call for access to abortion in religiously conservative countries

Zika virus threatens Brazil’s Olympic boost

From pharmaceuticals groups to cruise operators, companies are only starting to fathom the impact

Numbers games and existential angst

AstraZeneca and Shell chiefs take the stage, who gets applause?

Smith & Nephew makes products for orthopaedic reconstruction, such as hip replacements

S&N says results prove it can rival big groups

UK-listed medical device maker beats expectations

Spain confirms first pregnant Zika carrier

Health ministry in Catalonia says woman caught virus in Colombia

Activist investors: hard drugs

J&J is too tough a target for activists. How about Novartis?

Pharma holds key to US ratification of TPP

Obama’s Pacific trade deal hinges on Republican IP concerns

Shkreli refuses to testify before Congress

Pharma executive derides legislators as ‘imbeciles’

Irish comeback is no thanks to Brussels

Export-led revival has had little to do with ‘internal devaluation’

The force behind UK’s biotech successes

George Robinson has spent eight years helping build Adaptimmune and Immunocore

AstraZeneca warns on earnings for 2016

UK drugmaker insists turnround to meet generics test is on track

Witty avoids City’s would-be surgeons

GSK chief could be in store for bad news at yearly check-up

First IPOs of 2016 boost mood in biotech

Shares in BeiGene and Editas rise in early trading after closely watched Nasdaq listings

GSK defends strategy as new drugs lift sales

Target of £6bn annual sales from new products to be hit by 2018

Novo Nordisk lowers earnings targets

Health insurance group consolidation to increase buyer leverage

Pfizer says US cannot halt Allergan deal

‘We are operating under today’s laws’ says chief

GSK strengthens alliance with Adaptimmune

Drugmakers in deal to speed up trials of cancer medication


More FT Twitter accounts